Abstract

Lymphoproliferative disorders are disseminated in nature and hence therapy for the lymphoid malignancies has shown an increasing shift away from local therapy and toward systemic therapy. For a long time, cytotoxic chemotherapy has been the mainstay of systemic therapy for the lymphoid malignancies, but increasing knowledge about the basic molecular biology of these illnesses has resulted in the increasing use of agents targeted against key metabolic pathways responsible for carcinogenesis. In this chapter we will discuss the basic principles of action of the various individual chemotherapeutic agents, the rationale of combining two or more individual agents together, the concepts of high-dose chemotherapy with stem cell support, the newer targeted agents including monoclonal antibodies and small molecules that affect key intracellular pathways, and finally look at agents that are currently being investigated.

Original languageEnglish (US)
Title of host publicationThe Lymphoid Neoplasms 3ed
PublisherCRC Press
Pages872-893
Number of pages22
ISBN (Electronic)9781444113228
ISBN (Print)9780340809471
DOIs
StatePublished - Jan 1 2010

Fingerprint

Lymphoma
Drug Therapy
Lymphoproliferative Disorders
Therapeutics
Metabolic Networks and Pathways
Molecular Biology
Neoplasms
Carcinogenesis
Stem Cells
Monoclonal Antibodies

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Ganti, A. K. P., & Armitage, J. O. (2010). Systemic therapy of lymphoma. In The Lymphoid Neoplasms 3ed (pp. 872-893). CRC Press. https://doi.org/10.1201/b13424

Systemic therapy of lymphoma. / Ganti, Apar Kishor P; Armitage, James Olen.

The Lymphoid Neoplasms 3ed. CRC Press, 2010. p. 872-893.

Research output: Chapter in Book/Report/Conference proceedingChapter

Ganti, AKP & Armitage, JO 2010, Systemic therapy of lymphoma. in The Lymphoid Neoplasms 3ed. CRC Press, pp. 872-893. https://doi.org/10.1201/b13424
Ganti AKP, Armitage JO. Systemic therapy of lymphoma. In The Lymphoid Neoplasms 3ed. CRC Press. 2010. p. 872-893 https://doi.org/10.1201/b13424
Ganti, Apar Kishor P ; Armitage, James Olen. / Systemic therapy of lymphoma. The Lymphoid Neoplasms 3ed. CRC Press, 2010. pp. 872-893
@inbook{b51b2069957046d5b4dc9c80fba49b42,
title = "Systemic therapy of lymphoma",
abstract = "Lymphoproliferative disorders are disseminated in nature and hence therapy for the lymphoid malignancies has shown an increasing shift away from local therapy and toward systemic therapy. For a long time, cytotoxic chemotherapy has been the mainstay of systemic therapy for the lymphoid malignancies, but increasing knowledge about the basic molecular biology of these illnesses has resulted in the increasing use of agents targeted against key metabolic pathways responsible for carcinogenesis. In this chapter we will discuss the basic principles of action of the various individual chemotherapeutic agents, the rationale of combining two or more individual agents together, the concepts of high-dose chemotherapy with stem cell support, the newer targeted agents including monoclonal antibodies and small molecules that affect key intracellular pathways, and finally look at agents that are currently being investigated.",
author = "Ganti, {Apar Kishor P} and Armitage, {James Olen}",
year = "2010",
month = "1",
day = "1",
doi = "10.1201/b13424",
language = "English (US)",
isbn = "9780340809471",
pages = "872--893",
booktitle = "The Lymphoid Neoplasms 3ed",
publisher = "CRC Press",

}

TY - CHAP

T1 - Systemic therapy of lymphoma

AU - Ganti, Apar Kishor P

AU - Armitage, James Olen

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Lymphoproliferative disorders are disseminated in nature and hence therapy for the lymphoid malignancies has shown an increasing shift away from local therapy and toward systemic therapy. For a long time, cytotoxic chemotherapy has been the mainstay of systemic therapy for the lymphoid malignancies, but increasing knowledge about the basic molecular biology of these illnesses has resulted in the increasing use of agents targeted against key metabolic pathways responsible for carcinogenesis. In this chapter we will discuss the basic principles of action of the various individual chemotherapeutic agents, the rationale of combining two or more individual agents together, the concepts of high-dose chemotherapy with stem cell support, the newer targeted agents including monoclonal antibodies and small molecules that affect key intracellular pathways, and finally look at agents that are currently being investigated.

AB - Lymphoproliferative disorders are disseminated in nature and hence therapy for the lymphoid malignancies has shown an increasing shift away from local therapy and toward systemic therapy. For a long time, cytotoxic chemotherapy has been the mainstay of systemic therapy for the lymphoid malignancies, but increasing knowledge about the basic molecular biology of these illnesses has resulted in the increasing use of agents targeted against key metabolic pathways responsible for carcinogenesis. In this chapter we will discuss the basic principles of action of the various individual chemotherapeutic agents, the rationale of combining two or more individual agents together, the concepts of high-dose chemotherapy with stem cell support, the newer targeted agents including monoclonal antibodies and small molecules that affect key intracellular pathways, and finally look at agents that are currently being investigated.

UR - http://www.scopus.com/inward/record.url?scp=85056074264&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056074264&partnerID=8YFLogxK

U2 - 10.1201/b13424

DO - 10.1201/b13424

M3 - Chapter

SN - 9780340809471

SP - 872

EP - 893

BT - The Lymphoid Neoplasms 3ed

PB - CRC Press

ER -